DK2763981T3 - Fremgangsmåde til fremstilling af 1-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-on-hydrochlorid og mellemprodukter anvendt deri - Google Patents

Fremgangsmåde til fremstilling af 1-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-on-hydrochlorid og mellemprodukter anvendt deri Download PDF

Info

Publication number
DK2763981T3
DK2763981T3 DK12838558.0T DK12838558T DK2763981T3 DK 2763981 T3 DK2763981 T3 DK 2763981T3 DK 12838558 T DK12838558 T DK 12838558T DK 2763981 T3 DK2763981 T3 DK 2763981T3
Authority
DK
Denmark
Prior art keywords
fluorphenylamino
methoxyquinazolin
dichlor
yloxy
piperidin
Prior art date
Application number
DK12838558.0T
Other languages
Danish (da)
English (en)
Inventor
Keuk Chan Bang
Young Ho Moon
Young Kil Chang
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2763981(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Application granted granted Critical
Publication of DK2763981T3 publication Critical patent/DK2763981T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK12838558.0T 2011-10-05 2012-10-05 Fremgangsmåde til fremstilling af 1-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-on-hydrochlorid og mellemprodukter anvendt deri DK2763981T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110101422A KR101272613B1 (ko) 2011-10-05 2011-10-05 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
PCT/KR2012/008077 WO2013051883A2 (en) 2011-10-05 2012-10-05 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein

Publications (1)

Publication Number Publication Date
DK2763981T3 true DK2763981T3 (da) 2020-03-16

Family

ID=48044309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12838558.0T DK2763981T3 (da) 2011-10-05 2012-10-05 Fremgangsmåde til fremstilling af 1-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-on-hydrochlorid og mellemprodukter anvendt deri

Country Status (23)

Country Link
US (1) US8859767B2 (enExample)
EP (2) EP3611172A1 (enExample)
JP (1) JP5805880B2 (enExample)
KR (1) KR101272613B1 (enExample)
CN (2) CN110003174A (enExample)
AU (1) AU2012319291B2 (enExample)
BR (1) BR112014007718B1 (enExample)
CA (1) CA2850055C (enExample)
CY (1) CY1122758T1 (enExample)
DK (1) DK2763981T3 (enExample)
ES (1) ES2775197T3 (enExample)
HR (1) HRP20200426T1 (enExample)
HU (1) HUE048798T2 (enExample)
IL (3) IL231911B (enExample)
IN (1) IN2014DN03447A (enExample)
LT (1) LT2763981T (enExample)
MX (1) MX348815B (enExample)
PL (1) PL2763981T3 (enExample)
PT (1) PT2763981T (enExample)
RS (1) RS60118B1 (enExample)
RU (1) RU2563630C1 (enExample)
SI (1) SI2763981T1 (enExample)
WO (1) WO2013051883A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
JP6704422B2 (ja) 2015-03-20 2020-06-03 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. キナゾリン誘導体の塩およびその製造方法
KR102802129B1 (ko) * 2018-09-14 2025-05-02 한미약품 주식회사 퀴나졸린 화합물 및 이의 염산염의 결정 형태
KR101950942B1 (ko) * 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
US20210221792A1 (en) * 2020-01-16 2021-07-22 Hanmi Pharm Co., Ltd. Convergent synthesis of poziotinib derivative
WO2022043923A1 (en) * 2020-08-28 2022-03-03 Hanmi Science Co., Ltd. Synthesis of poziotinib derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
JP2009518450A (ja) * 2005-12-12 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環化合物、その化合物を含む薬剤、その使用及び製造方法
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
US8450482B2 (en) * 2009-04-23 2013-05-28 Astrazeneca Ab Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline

Also Published As

Publication number Publication date
HUE048798T2 (hu) 2020-08-28
EP2763981A2 (en) 2014-08-13
LT2763981T (lt) 2020-05-25
ES2775197T3 (es) 2020-07-24
JP2014528444A (ja) 2014-10-27
EP2763981B1 (en) 2020-01-08
CN103857672B (zh) 2018-11-30
JP5805880B2 (ja) 2015-11-10
WO2013051883A2 (en) 2013-04-11
CA2850055E (en) 2013-04-11
EP2763981A4 (en) 2015-02-25
CA2850055C (en) 2016-05-17
US20140275534A1 (en) 2014-09-18
CA2850055A1 (en) 2013-04-11
IL231911A0 (en) 2014-05-28
US8859767B2 (en) 2014-10-14
IN2014DN03447A (enExample) 2015-06-26
CN110003174A (zh) 2019-07-12
BR112014007718A2 (pt) 2017-04-25
RS60118B1 (sr) 2020-05-29
PT2763981T (pt) 2020-03-25
PL2763981T3 (pl) 2020-08-10
RU2563630C1 (ru) 2015-09-20
EP3611172A1 (en) 2020-02-19
IL259694A (en) 2018-07-31
BR112014007718B1 (pt) 2022-02-22
CY1122758T1 (el) 2021-03-12
MX2014003959A (es) 2014-05-14
CN103857672A (zh) 2014-06-11
IL291738A (en) 2022-05-01
WO2013051883A3 (en) 2013-06-06
IL231911B (en) 2018-06-28
HRP20200426T1 (hr) 2020-09-04
SI2763981T1 (sl) 2020-07-31
KR20130037079A (ko) 2013-04-15
KR101272613B1 (ko) 2013-06-10
AU2012319291A1 (en) 2014-05-22
IL259694B (en) 2022-04-01
MX348815B (es) 2017-06-30
AU2012319291B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
DK2763981T3 (da) Fremgangsmåde til fremstilling af 1-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-on-hydrochlorid og mellemprodukter anvendt deri
HUS1900012I1 (hu) Vegyületek és készítmények protein-kináz inhibitorokként
DK2501692T3 (da) Fremgangsmåde til fremstilling af dabigatranetexilat
SMT201600057B (it) 3,5-diammino-6-cloro-n-(n-(4-(4-(2-(esil(2,3,4,5,6-pentaidrossiesil)ammino)etossi)fenil)butil)- carbammimidoil)pirazina-2-carbossammide
HRP20190398T1 (hr) Čvrsti oblik (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidroklorida
DK4082530T3 (da) Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme
DK2247582T3 (da) Vandfri, krystallinsk form af dimethoxydocetaxel og fremgangsmåder til fremstilling heraf
DK3012329T3 (da) Fremgangsmåder og materialer til at vurdere tab af heterozygositet
DK2794907T4 (da) Fremgangsmåder og materialer til vurdering af tab af heterozygositet
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2882442T3 (da) Fremgangsmåder til behandling af cancer under anvendelse af 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion
DK2683708T3 (da) Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
DK2358691T3 (da) Fremgangsmåde til fremstilling af piperazinforbindelser og hydrochloridsalte deraf
DK2921491T3 (da) Mellemforbindelser til fremstilling af heteroarylpiperidiner og ¿piperazinderivater som fungicider
DK3409278T3 (da) Heterocykliske proteinkinaseinhibitorer
DK2297132T3 (da) Fremgangsmåde til fremstilling af et mellemprodukt af dabigatran-etexilat
DK3054927T3 (da) Formuleringer af (s)-3-(4-((4-morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion
DK2315750T3 (da) Forbedret fremgangsmåde til fremstilling af 2-trifluormethyl-5-(1-substituerede) alkylpyridiner
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
DK3210991T3 (da) Krystallinsk form af levoisovalerylspiramycin ii og præparater, fremstillingsfremgangsmåder og anvendelser deraf
DK2462098T3 (da) Fremgangsmåde til fremstillingen af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre
DK2459528T3 (da) 2-(3-alkylthiobenzoyl) cyclohexandion og anvendelsen heraf som herbicider
DK2786757T3 (da) 2-substitueret oleanolsyre-derivat, fremgangsmåde til fremstilling af samme, og anvendelse deraf
DK2392548T3 (da) Fremgangsmåde til fremstilling af en amorf siliciumdioxid-sammensætning og beslægtet amorf siliciumdioxid-aluminiumoxid-samensætning
DK2204364T3 (da) Polymorfer af donepezil-salte, fremgangsmåder til fremstilling og anvendelser deraf